+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antineoplastic Agents Market by Product Type, Route Of Administration, Indication, Distribution Channel - Global Forecast to 2030- Product Image
Antineoplastic Agents Market by Product Type, Route Of Administration, Indication, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Antineoplastic Agents Market by Product Type, Route Of Administration, Indication, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5887460
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antineoplastic Agents Market grew from USD 143.82 billion in 2024 to USD 158.96 billion in 2025. It is expected to continue growing at a CAGR of 10.44%, reaching USD 260.98 billion by 2030.

Introduction to the Evolving Antineoplastic Market

The antineoplastic agents space stands at the forefront of medical innovation, driven by the relentless pursuit of more effective and targeted cancer therapies. Over the past decade, breakthroughs in molecular biology and immunology have redefined the possibilities for treating hematological cancers and solid tumors alike, elevating patient outcomes and revealing new avenues for clinical intervention. In this context, both established pharmaceutical giants and nimble biotech disruptors compete to translate cutting-edge discoveries into commercially viable treatments, creating a dynamic and competitive market environment.

Against this backdrop, stakeholders across the value chain-from raw material suppliers and contract manufacturers to health care providers and payers-must navigate an intricate network of regulatory requirements, supply-chain dependencies, and evolving reimbursement landscapes. Robust strategic planning and data-driven decision-making are vital to capitalize on emerging opportunities while mitigating risks. This report provides an executive overview of the factors shaping today’s antineoplastic market, setting the stage for deeper analysis of the forces driving growth, segmentation dynamics, regional trends, and actionable recommendations for industry leaders.

Emerging Dynamics Reshaping Cancer Therapy Innovations

Innovations in immuno-oncology have catalyzed a seismic shift in the antineoplastic sector, with checkpoint inhibitors, CAR-T therapies, and bispecific antibodies moving from experimental stages into routine clinical use. Precision medicine approaches leverage genomic profiling to tailor treatments, enabling the development of companion diagnostics and targeted therapies that improve efficacy while minimizing off-target effects. Concurrently, advances in formulation science have spawned next-generation delivery systems-such as antibody-drug conjugates and nanoparticle carriers-that enhance drug bioavailability and tumor penetration.

Digital health platforms further accelerate this transformation by facilitating remote monitoring, real-world evidence generation, and adaptive clinical trial designs. Artificial intelligence and machine learning algorithms optimize trial enrollment, expedite drug discovery workflows, and predict patient responses. Meanwhile, global partnerships between academia, biotech start-ups, and large pharma organizations encourage knowledge sharing and risk-sharing models that reduce time-to-market. Collectively, these developments signal a departure from one-size-fits-all chemotherapy regimens toward more sophisticated, individualized treatment paradigms.

Unraveling the Impact of New US Tariffs on Oncology Agents

The introduction of new United States tariffs in 2025 has had a material effect on the procurement costs of key active pharmaceutical ingredients and critical raw materials used in antineoplastic production. Manufacturers reliant on imports from major API hubs have seen input costs escalate, prompting strategic shifts in supplier portfolios. Contract manufacturing organizations are reassessing their global footprints, with some opting to reshuffle production to domestic or near-shoring facilities to insulate against further tariff volatility.

These cost pressures have rippled through the distribution network, impacting pricing negotiations with payers and hospital systems. In several cases, manufacturers have renegotiated supply agreements to incorporate cost-containment clauses or volume-based rebates. At the same time, regulatory agencies have signaled potential relief measures for therapies deemed essential to public health, offering accelerated review pathways or temporary duty exemptions. Moving forward, companies will need to balance cost mitigation tactics with investment in process innovation to maintain margins and ensure uninterrupted patient access.

Decoding Market Segments Driving Oncology Advancements

Product type segmentation reveals a diverse portfolio of treatment modalities. Cytotoxic agents remain foundational, with alkylating compounds, antimetabolites, and mitotic inhibitors still prescribed extensively. Hormonal agents continue to play a critical role in hormone-driven malignancies, encompassing antiestrogens, aromatase inhibitors, and LHRH agonists. Immunomodulatory therapies have surged in prominence, especially monoclonal antibodies targeting CD20, HER2, and PD-1/PD-L1, alongside small molecule tyrosine kinase inhibitors that inhibit BCR-ABL, EGFR, and VEGF signaling pathways.

The route of administration shapes treatment protocols and patient experience. Intravenous infusions dominate hospital settings, while oral regimens offer greater convenience and adherence in outpatient contexts. Subcutaneous formulations are emerging as a compromise, enabling faster administration and reduced infusion-related complications. Indication-based segmentation highlights distinct clinical pathways: hematological cancers, including leukemia, lymphoma, and multiple myeloma, benefit tremendously from targeted biologics and cell therapies, while solid tumors such as breast, colorectal, and lung cancer-further refined into non-small cell and small cell subtypes-drive demand for combination regimens and novel targeted inhibitors. Distribution channels mirror the evolving care continuum, with hospital pharmacies remaining the primary fulcrum, supplemented by online pharmacies that cater to home administration needs, and retail pharmacies providing local access for maintenance therapies.

Regional Variations Illuminating Global Oncology Trends

The Americas region continues to lead in oncology innovation, buoyed by strong R&D investments, supportive regulatory frameworks, and high per-capita health care spending that facilitate rapid therapy adoption. Strategic partnerships and acquisitions are particularly prevalent, as companies vie for first-mover advantage in immunotherapies and personalized vaccines. Europe, Middle East & Africa exhibit heterogeneous dynamics: core European markets benefit from centralized pricing negotiations and collaborative research consortia, while emerging markets in the Middle East and Africa grapple with access challenges, infrastructure constraints, and nascent reimbursement systems.

Asia-Pacific has emerged as a dynamic growth frontier, propelled by expanding clinical trial activities, growing biotech ecosystems, and favorable government initiatives to bolster domestic pharmaceutical manufacturing. China and Japan stand out with robust pipelines and aggressive innovation agendas, whereas Southeast Asian markets demonstrate rapid uptake of generic and biosimilar offerings. Across all regions, payer models and health technology assessment frameworks continue to evolve, influencing market entry strategies and portfolio prioritization for antineoplastic stakeholders.

Spotlight on Industry Trailblazers and Strategic Moves

The competitive landscape is spearheaded by multinational pharmaceutical corporations that maintain extensive oncology portfolios and leverage global scale to drive volume-based efficiencies. Biotech innovators have carved out specialized niches, focusing on novel modalities such as antibody-drug conjugates and gene-edited cell therapies. Several midsized players have successfully deployed strategic alliances and licensing agreements to access late-stage assets, accelerating commercialization timelines and complementing their in-house R&D capabilities.

Contract research and manufacturing organizations play an increasingly critical role, offering end-to-end solutions that range from early discovery to commercial­scale production. Their agility and deep technical expertise allow for rapid process optimization and cost control, enabling sponsors to de-risk development programs. Across the board, collaborations between academia and industry continue to spawn breakthrough platforms, while strategic mergers and acquisitions reshape competitive dynamics and foster pipeline diversification.

Strategic Imperatives for Future-Proofing Market Leadership

Industry leaders should prioritize investment in flexible manufacturing platforms to accommodate the growing diversity of antineoplastic modalities and mitigate tariff-induced cost risks. Establishing regional centers of excellence for cell- and gene-based therapies can enhance supply-chain resilience and expedite patient access. Simultaneously, integrating digital health tools into clinical and commercial operations will drive real-world data generation, support value-based contracting, and strengthen payer negotiations.

Adopting risk-sharing agreements and outcome-based reimbursement models can improve market access while aligning incentives with health systems. To capitalize on emerging markets, companies should forge public-private partnerships that address infrastructure gaps and streamline regulatory approvals. Cultivating cross-sector alliances with diagnostics developers, contract service providers, and patient advocacy groups will ensure a holistic approach to therapy development and adoption, sustaining growth in an increasingly competitive environment.

Rigorous Approach Underpinning Our Research Framework

This research integrates primary insights from in-depth interviews with industry executives, clinicians, and regulatory experts, complemented by secondary analysis of peer-reviewed literature, patent filings, and government publications. Proprietary databases provided granular intelligence on drug pipelines, clinical trial landscapes, and manufacturing capacities. Data validation techniques included triangulation of multiple sources, cross-referencing of regional regulatory filings, and consistency checks against historical benchmarks.

Quantitative assessments focused on segmentation dynamics and pricing impacts, while qualitative narratives explored innovation drivers and strategic imperatives. Expert review panels ensured the analytical rigor and relevance of our findings. This multifaceted approach delivers a balanced perspective, combining empirical data with actionable insights tailored for decision-makers across the antineoplastic value chain.

Synthesizing Insights for a Cohesive Market Perspective

The antineoplastic market exists at an inflection point where scientific breakthroughs, economic considerations, and regulatory shifts converge to redefine industry paradigms. The interplay between innovation in targeted therapies, evolving payer models, and global supply chain dynamics necessitates a holistic view of the competitive landscape. Companies that actively embrace manufacturing agility, invest in digital and data capabilities, and foster collaborative partnerships will be best positioned to navigate tariff headwinds and regulatory complexities.

As regional markets mature and diversify, a nuanced understanding of segmentation dynamics-from product classes and administration routes to clinical indications and distribution pathways-will inform strategic portfolio planning. Ultimately, the organizations that synthesize these insights into cohesive, patient-centric strategies will accelerate the translation of scientific advances into improved clinical outcomes and sustainable commercial success.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Cytotoxic Agents
      • Alkylating Agents
      • Antimetabolites
      • Mitotic Inhibitors
    • Hormonal Agents
      • Anti Estrogens
      • Aromatase Inhibitors
      • Lhrh Agonists
    • Immunomodulators
    • Monoclonal Antibodies
      • Anti Cd20 Antibodies
      • Anti Her2 Antibodies
      • Anti Pd-1/Pd-L1 Inhibitors
    • Tyrosine Kinase Inhibitors
      • Bcr-Abl Inhibitors
      • Egfr Inhibitors
      • Vegf Inhibitors
  • Route Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • Indication
    • Hematological Cancer
      • Leukemia
      • Lymphoma
      • Multiple Myeloma
    • Solid Tumor
      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
        • Non Small Cell Lung Cancer
        • Small Cell Lung Cancer
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Roche Holding AG
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca PLC
  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly and Company

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antineoplastic Agents Market, by Product Type
8.1. Introduction
8.2. Cytotoxic Agents
8.2.1. Alkylating Agents
8.2.2. Antimetabolites
8.2.3. Mitotic Inhibitors
8.3. Hormonal Agents
8.3.1. Anti Estrogens
8.3.2. Aromatase Inhibitors
8.3.3. Lhrh Agonists
8.4. Immunomodulators
8.5. Monoclonal Antibodies
8.5.1. Anti Cd20 Antibodies
8.5.2. Anti Her2 Antibodies
8.5.3. Anti Pd-1/Pd-L1 Inhibitors
8.6. Tyrosine Kinase Inhibitors
8.6.1. Bcr-Abl Inhibitors
8.6.2. Egfr Inhibitors
8.6.3. Vegf Inhibitors
9. Antineoplastic Agents Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Antineoplastic Agents Market, by Indication
10.1. Introduction
10.2. Hematological Cancer
10.2.1. Leukemia
10.2.2. Lymphoma
10.2.3. Multiple Myeloma
10.3. Solid Tumor
10.3.1. Breast Cancer
10.3.2. Colorectal Cancer
10.3.3. Lung Cancer
10.3.3.1. Non Small Cell Lung Cancer
10.3.3.2. Small Cell Lung Cancer
11. Antineoplastic Agents Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Americas Antineoplastic Agents Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Antineoplastic Agents Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Antineoplastic Agents Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Roche Holding AG
15.3.2. Merck & Co., Inc.
15.3.3. Johnson & Johnson
15.3.4. Bristol-Myers Squibb Company
15.3.5. Novartis AG
15.3.6. Pfizer Inc.
15.3.7. AstraZeneca PLC
15.3.8. AbbVie Inc.
15.3.9. Amgen Inc.
15.3.10. Eli Lilly and Company
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ANTINEOPLASTIC AGENTS MARKET MULTI-CURRENCY
FIGURE 2. ANTINEOPLASTIC AGENTS MARKET MULTI-LANGUAGE
FIGURE 3. ANTINEOPLASTIC AGENTS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ANTINEOPLASTIC AGENTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ANTINEOPLASTIC AGENTS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTINEOPLASTIC AGENTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY MITOTIC INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ANTI ESTROGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LHRH AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ANTI CD20 ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ANTI HER2 ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ANTI PD-1/PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 74. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 75. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 76. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 77. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 78. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 81. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 82. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 83. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 84. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 86. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 87. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 88. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 89. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 93. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 94. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 95. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 142. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 143. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 144. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 145. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 146. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 149. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 150. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 151. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 153. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 154. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 155. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 156. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 157. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 159. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 160. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 161. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 162. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. RUSSIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 171. RUSSIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. ITALY ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 175. ITALY ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 176. ITALY ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 177. ITALY ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 178. ITALY ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 179. ITALY ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. ITALY ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 181. ITALY ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 182. ITALY ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 183. ITALY ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 184. ITALY ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. SPAIN ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 186. SPAIN ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 187. SPAIN ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 188. SPAIN ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 189. SPAIN ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 190. SPAIN ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. SPAIN ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 192. SPAIN ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 193. SPAIN ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 194. SPAIN ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 195. SPAIN ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 203. UNITED ARAB EMIRATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 204. UNITED ARAB EMIRATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 206. UNITED ARAB EMIRATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 212. SAUDI ARABIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. SAUDI ARABIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 214. SAUDI ARABIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 215. SAUDI ARABIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 216. SAUDI ARABIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 217. SAUDI ARABIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. SOUTH AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 225. SOUTH AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 226. SOUTH AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 227. SOUTH AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 228. SOUTH AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. DENMARK ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 230. DENMARK ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 231. DENMARK ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 232. DENMARK ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 233. DENMARK ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 234. DENMARK ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. DENMARK ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 236. DENMARK ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 237. DENMARK ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 238. DENMARK ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 239. DENMARK ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 244. NETHERLANDS ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 245. NETHERLANDS ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. NETHERLANDS ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 247. NETHERLANDS ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 248. NETHERLANDS ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 249. NETHERLANDS ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 250. NETHERLANDS ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. QATAR ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 252. QATAR ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 253. QATAR ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 254. QATAR ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 255. QATAR ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 256. QATAR ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. QATAR ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 258. QATAR ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 259. QATAR ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 260. QATAR ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 261. QATAR ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. FINLAND ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 263. FINLAND ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 264. FINLAND ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 265. FINLAND ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 266. FINLAND ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 267. FINLAND ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. FINLAND ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 269. FINLAND ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 270. FINLAND ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 271. FINLAND ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 272. FINLAND ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 276. SWEDEN ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 277. SWEDEN ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 278. SWEDEN ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. SWEDEN ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 280. SWEDEN ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 281. SWEDEN ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 282. SWEDEN ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 283. SWEDEN ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 288. NIGERIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 289. NIGERIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 290. NIGERIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 291. NIGERIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 292. NIGERIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 293. NIGERIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 294. NIGERIA ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. EGYPT ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 296. EGYPT ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 297. EGYPT ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 298. EGYPT ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 299. EGYPT ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 300. EGYPT ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. EGYPT ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 302. EGYPT ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 303. EGYPT ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 304. EGYPT ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 305. EGYPT ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. TURKEY ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 307. TURKEY ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 308. TURKEY ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 309. TURKEY ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 310. TURKEY ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 311. TURKEY ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 312. TURKEY ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 313. TURKEY ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 314. TURKEY ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 315. TURKEY ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 316. TURKEY ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2030 (USD MILLION)
TABLE 319. ISRAEL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2030 (USD MILLION)
TABLE 320. ISRAEL ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 321. ISRAEL ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 322. ISRAEL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 323. ISRAEL A

Companies Mentioned

The companies profiled in this Antineoplastic Agents market report include:
  • Roche Holding AG
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca PLC
  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly and Company

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 158.96 Billion
Forecasted Market Value ( USD ) by 2030 $ 260.98 Billion
Compound Annual Growth Rate10.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antineoplastic Agents - Global Strategic Business Report - Product Image

Antineoplastic Agents - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Taxane Antineoplastic Drug Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Taxane Antineoplastic Drug Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 115 Pages
  • Global
From
Neurological Complications of Systemic Cancer and Antineoplastic Therapy. Edition No. 2 - Product Image

Neurological Complications of Systemic Cancer and Antineoplastic Therapy. Edition No. 2

  • Book
Anti-Neoplastic Agents Market Report 2025 - Product Image

Anti-Neoplastic Agents Market Report 2025

  • Report
  • 200 Pages
  • Global
From
New Strategies Targeting Cancer Metabolism. Anticancer Drugs, Synthetic Analogues and Antitumor Agents - Product Image

New Strategies Targeting Cancer Metabolism. Anticancer Drugs, Synthetic Analogues and Antitumor Agents

  • Book
Copyright © 2002-2025 Research and Markets. All Rights Reserved.